Active Ingredient History
CRESTOR (rosuvastatin calcium) is an inhibitor of HMG-CoA reductase. It has been widely launched for the treatment of patients with dyslipidaemia and has also been approved in the US and EU to slow the progression of atherosclerosis. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Atherosclerosis (approved 2003)
Dyslipidemias (approved 2003)
Hyperlipoproteinemia Type II (approved 2003)
Hyperlipoproteinemia Type III (approved 2003)
Hypertriglyceridemia (approved 2003)
22q11 Deletion Syndrome (Phase 4)
Acute Coronary Syndrome (Phase 4)
Acute Lung Injury (Phase 3)
Aged (Phase 1)
Anemia (Phase 1)
Anemia, Sickle Cell (Phase 1)
Angina Pectoris (Phase 4)
Angioedemas, Hereditary (Phase 1)
Angioplasty (Phase 4)
Angioplasty, Balloon, Coronary (Phase 1)
Aortic Valve Stenosis (Phase 3)
Arteriovenous Fistula (Phase 2)
Arthritis, Psoriatic (Phase 4)
Arthritis, Rheumatoid (Phase 2/Phase 3)
Asthma (Phase 1)
Atherosclerosis (Phase 4)
Atrial Fibrillation (Phase 4)
Autoimmune Diseases (Phase 1)
Blood Platelet Disorders (Phase 2)
Blood Platelets (Phase 1)
Blood Pressure (Phase 2/Phase 3)
Breast Neoplasms (Phase 3)
Burns (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 1)
Carcinoma, Squamous Cell (Phase 1)
Cardiomyopathy, Dilated (Phase 3)
Cardiovascular Diseases (Phase 4)
Carotid Artery Diseases (Phase 4)
Carotid Stenosis (Phase 3)
Cerebral Hemorrhage (Phase 2)
Cerebral Infarction (Phase 4)
Cholangitis, Sclerosing (Early Phase 1)
Chronic Periodontitis (Phase 4)
Clonal Hematopoiesis (Phase 2)
Cognitive Dysfunction (Phase 3)
Colitis, Ulcerative (Phase 2/Phase 3)
Colorectal Neoplasms (Phase 3)
Coronary Artery Disease (Phase 4)
Coronary Disease (Phase 4)
COVID-19 (Phase 1)
Craniocerebral Trauma (Phase 2)
C-Reactive Protein (Phase 3)
Critical Illness (Phase 2)
Cytochrome P-450 CYP2C19 (Phase 1)
Dehydration (Phase 4)
Depression (Phase 2)
Diabetes Mellitus (Phase 4)
Diabetes Mellitus, Type 2 (Phase 4)
Diabetic Neuropathies (Phase 2)
Diagnostic Self Evaluation (Phase 1)
Drug Interactions (Phase 4)
Dual Anti-Platelet Therapy (Phase 2)
Dyslipidemias (Phase 4)
Endocrine System Diseases (Phase 4)
Endometrial Hyperplasia (Phase 2/Phase 3)
Endometrial Neoplasms (Phase 2)
Endomyocardial Fibrosis (Phase 4)
Endothelial Cells (Phase 4)
Endotoxemia (Phase 1)
Esophageal and Gastric Varices (Phase 2/Phase 3)
Essential Hypertension (Phase 3)
Fibrosis (Phase 2/Phase 3)
Friedreich Ataxia (Early Phase 1)
Furcation Defects (Phase 4)
General Surgery (Phase 3)
Glaucoma (Phase 4)
Glomerular Filtration Rate (Phase 2/Phase 3)
Healthy Volunteers (Phase 4)
Heart (Phase 4)
Heart Disease Risk Factors (Phase 4)
Heart Diseases (Phase 4)
Heart Failure (Phase 4)
Heart Failure, Diastolic (Phase 4)
Heart Failure, Systolic (Phase 4)
Hepacivirus (Phase 1)
Hepatitis B (Phase 2)
Hepatitis B, Chronic (Phase 1)
Hepatitis C (Phase 2)
Hepatitis C, Chronic (Phase 2)
Hip Fractures (Phase 3)
HIV (Phase 4)
HIV Infections (Phase 4)
HIV Seropositivity (Early Phase 1)
Homozygous Familial Hypercholesterolemia (Phase 3)
Hypercholesterolemia (Phase 4)
Hyperglycemia (Phase 4)
Hyperlipidemias (Phase 4)
Hyperlipoproteinemia Type II (Phase 4)
Hyperlipoproteinemia Type III (Phase 3)
Hyperlipoproteinemia Type IV (Phase 4)
Hyperlipoproteinemia Type V (Phase 4)
Hypertension (Phase 4)
Hypertension, Portal (Phase 2/Phase 3)
Hypertriglyceridemia (Phase 4)
Immunosuppression Therapy (Phase 1)
Infarction, Anterior Cerebral Artery (Phase 4)
Inflammation (Phase 1)
Inflammatory Bowel Diseases (Early Phase 1)
Influenza A Virus, H1N1 Subtype (Phase 2)
Insulin Resistance (Phase 4)
Intestinal Absorption (Phase 1)
Intracranial Arterial Diseases (Phase 4)
Intracranial Arteriosclerosis (Phase 4)
Ischemia (Phase 4)
Ischemic Attack, Transient (Phase 4)
Ischemic Stroke (Phase 4)
Kidney Diseases (Phase 4)
Kidney Failure, Chronic (Phase 2)
Kidney Transplantation (Phase 4)
Leukemia, Myeloid, Acute (Phase 1)
Lipids (Phase 2/Phase 3)
Lipoproteins (Phase 4)
Liver Cirrhosis (Phase 2)
Liver Cirrhosis, Biliary (Phase 2)
Lupus Erythematosus, Systemic (Phase 4)
Malaria (Phase 1)
Melanoma (Phase 1)
Metabolic Diseases (Phase 1)
Metabolic Syndrome (Phase 4)
Metabolism (Phase 4)
Molecular Imaging (Phase 4)
Myelodysplastic Syndromes (Phase 2)
Myocardial Infarction (Phase 4)
Myocardial Ischemia (Phase 3)
Myocardial Stunning (Phase 4)
Myocardium (Phase 3)
Neoplasms (Phase 2)
Non-alcoholic Fatty Liver Disease (Phase 4)
Nutritional and Metabolic Diseases (Phase 4)
Obesity (Phase 1)
Obesity, Abdominal (Phase 3)
Osteoporosis (Phase 2)
Ovarian Neoplasms (Phase 2)
Oxidative Stress (Phase 2)
Parkinson Disease (Phase 1)
Percutaneous Coronary Intervention (Phase 4)
Periodontitis (Phase 4)
Peripheral Arterial Disease (Phase 4)
Pharmacokinetics (Phase 1)
Postthrombotic Syndrome (Phase 3)
Precancerous Conditions (Phase 3)
Pre-Eclampsia (Phase 2)
Primary Prevention (Phase 4)
Prostatic Neoplasms (Phase 1)
Proteinuria (Phase 4)
Psoriasis (Phase 4)
Pulmonary Disease, Chronic Obstructive (Phase 2)
Pulmonary Embolism (Phase 3)
Rectal Neoplasms (Phase 2)
Renal Artery Obstruction (Phase 2/Phase 3)
Renal Insufficiency (Phase 3)
Renal Insufficiency, Chronic (Phase 4)
Reperfusion Injury (Phase 4)
Respiratory Syncytial Virus Infections (Phase 1)
Rosuvastatin Calcium (Phase 4)
SARS-CoV-2 (Phase 3)
Scleroderma, Systemic (Phase 3)
Sedentary Behavior (Phase 4)
Sepsis (Phase 3)
Sexual Dysfunction, Physiological (Phase 4)
Skin Diseases, Bacterial (Phase 1)
Spinal Cord Injuries (Phase 2)
Sports Medicine (Phase 4)
ST Elevation Myocardial Infarction (Phase 4)
Stents (Phase 2/Phase 3)
Stroke (Phase 4)
Telomere (Phase 4)
Telomere Shortening (Phase 4)
Therapeutic Equivalency (Phase 1)
Thromboembolism (Phase 4)
Thrombosis (Phase 4)
Tomography (Phase 3)
Toxicity Tests (Phase 3)
Tuberculosis, Pulmonary (Phase 2)
Upper Extremity Deep Vein Thrombosis (Phase 1/Phase 2)
Vasomotor System (Phase 1)
Venous Cutdown (Phase 4)
Venous Thromboembolism (Phase 4)
Venous Thrombosis (Phase 4)
Volunteers (Phase 1)
Wounds and Injuries (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue